AI English summary of an SEC filing — figures as filed
Kenvue KVUEThe company said net sales were $7.9 billion for the 6 months ended June 30, 2024, flat from a year earlier, and $31 million, or 0.4%, higher. Excluding the $103 million impact of currency rates, organic growth was $134 million. It said value realization partially offset volume declines.
Key points
AI summaryThe company said net sales were $7.9 billion for the 6 months ended June 30, 2024, flat from a year earlier, and $31 million, or 0.4%, higher. Excluding the $103 million impact of currency rates, organic growth was $134 million. It said value realization partially offset volume declines.
The company said impairment charges were $578 million over the 6 months, of which a non-cash charge of $488 million ($337 million after-tax) related to the Dr.Ci:Labo skin health business was the main item. The company cited revisions to its internal outlook, reflecting changes in consumer sentiment in China, as the reason.
The company said gross profit margin was 58.4% for the 6 months, up from 55.3% a year earlier, an expansion of 310 basis points. It said selling, general, and administrative expenses rose to 40.7% of net sales, an increase of 220 basis points, citing higher brand marketing expenses.
Kenvue said net cash flows from operating activities were $727 million for the 6 months, down $817 million from $1,544 million a year earlier. In financing, it paid $766 million in dividends and spent $91 million on treasury share purchases. Cash and cash equivalents were $1,014 million as of June 30.
Key figures
Quarter ended June 30, 2024
- Revenue
- $4.0B
- Operating income
- $154M
- Net income
- $58M
- EPS
- $0.03
- Gross profit
- $2.4B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Kenvue 6-month net sales flat, $7.9 billion and $31 million higher
The company said net sales were $7.9 billion for the 6 months ended June 30, 2024, flat from a year earlier, and $31 million, or 0.4%, higher. Excluding the $103 million impact of currency rates, organic growth was $134 million. It said value realization partially offset volume declines.
Source · Based on the MD&A text of the filing
Kenvue 6-month impairment charges at $578 million
The company said impairment charges were $578 million over the 6 months, of which a non-cash charge of $488 million ($337 million after-tax) related to the Dr.Ci:Labo skin health business was the main item. The company cited revisions to its internal outlook, reflecting changes in consumer sentiment in China, as the reason.
Source · Based on the MD&A text of the filing
Gross profit margin at 58.4%, SG&A ratio at 40.7%
The company said gross profit margin was 58.4% for the 6 months, up from 55.3% a year earlier, an expansion of 310 basis points. It said selling, general, and administrative expenses rose to 40.7% of net sales, an increase of 220 basis points, citing higher brand marketing expenses.
Source · Based on the MD&A text of the filing
Kenvue 6-month operating cash flow $727 million, dividends and share buybacks
Kenvue said net cash flows from operating activities were $727 million for the 6 months, down $817 million from $1,544 million a year earlier. In financing, it paid $766 million in dividends and spent $91 million on treasury share purchases. Cash and cash equivalents were $1,014 million as of June 30.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
You can verify the report’s figures and statements in the original filing on SEC EDGAR.